Interview with Bob Schneiderman, the CEO of SCRC - Nov. 02, 2012

About ScripsAmerica, Inc.

ScripsAmerica, Inc. delivers pharmaceutical products to a wide range of end users across the health care industry, including physicians' offices, retail pharmacies, long-term care sites, hospitals, and Government and home care agencies through the largest pharmaceutical distributor in North America, McKesson Corporation. Current therapeutic categories serviced by the Company include pain, arthritis, prenatal, urinary, and hormonal replacement drugs. Other customers of ScripsAmerica include Cardinal Health, CutisPharma, Inc, MedVet and the United States Veterans Administration. www.ScripsAmerica.com.

(NEW YORK)--ScripsAmerica, Inc. (OTC:SCRC), a leading supplier of prescription, OTC and nutraceutical drugs to US government agencies, announced in their fiscal 2012 results that they have restarted their generic drug contract with the Veteran’s Administration.

Investor Highlights

- Generic Drug Supplier to US Govt. Agencies
- Renews Generic Drug Shipments to VA
- Over-the-Counter Product Launch in Q2
- RapiMed Product to take on Children's Tylenol Meltaway’s
- Projecting $10 Million in Sales for 2013
- Pending Merger with Marlex Pharmaceuticals
- $25 million Contract with US Dept. of Homeland Security

2012 Financial Results

For the twelve months ending Dec. 31, 2012, the Company reported total revenues of $3,915,000, as compared to $5,956,000 for same period in 2011. In their filing they commented that the decline in sales versus the 2011 period was mainly a result of the completion of a supply agreement with the Veteran’s Administration (VA) in 2011, but did confirm the Company has renewed their VA contract in the fourth quarter of 2012, and revenues would have been approximately $1 million higher in 2012.

Projecting $10 Million Sales for 2013

During the first quarter 2013, the Company projected strong revenue sales growth based on renewing contracts. The Company recorded its highest monthly revenue ever of $904,275 in January, followed by $849,039 in February, a 115% increase over February 2012. Management believes it is on pace to record its highest annual sales ever, and achieve an important milestone of $10 million+ in revenues for 2013.

RapiMed(R) Over-the-Counter Product Launch

During 2012, the Company worked in developing and market its RapiMed® pediatric pain and fever reliever over-the-counter product, and anticipates national distribution launch in the second quarter of 2013. In February, the Company obtained positive feedback at the 2013 "Cough/Cold, Analgesics & Allergy EPPS" conference, and received verbal order commitments from 62 of 66 retailers that it met with during the conference. The launch of ScripsAmerica’s unique pain and fever relief product should provide for additional revenue growth as the company focuses on expanding its national distribution through the summer 2013, and gaining market share from McNeil Consumer Healthcare's ‘Tylenol Meltaways'. http://www.rapimeds.com

Marlex Pharmaceuticals Acquisition

On Sept. 12, 2012, the Company announced it had signed a Letter of Intent (LOI) to acquire Marlex Pharmaceuticals, Inc., a global pharmaceutical packaging company.

The acquisition is expected to have a positive impact on both companies, and could add 10-15% to ScripsAmerica's gross profit margin. More specifically, the Company forecasts that this move would significantly increase its revenues by up to $6 million, order processing capability, and profitability in addition to providing more opportunities to secure government contracts due to Marlex's current relationships. Marlex would add strong management with years of experience in the pharmaceutical products field to the SCRC team.

Marlex Pharmaceuticals' New Castle, DE facility is in compliance with the FDA, DEA, and the state board of pharmacy and contains 12,000 square feet of temperature-controlled space dedicated to pharmaceutical packaging, contract packaging and private labeling.

$25 Million Govt. Contract

On Sept. 24, 2012, the Company announced their pending acquisition, Marlex Pharmaceuticals, Inc, was awarded a $25 million pharmaceutical distribution contract with the Office of Health Affairs, a branch of the U.S. Department of Homeland Security, in conjunction with the Defense Logistics Agency (DLA).

Marlex will supply pharmaceuticals to the DLA over the next 2-3 years at a cost of $25 million, and was awarded this contract based on the company's ability to provide specified pharmaceuticals at competitive prices. On Oct. 05, 2012, the Company has already shipped and invoiced the first order of an 8 year pharmaceutical distribution contract with the United States Department of Defense and Defense Logistics Agency (DLA).

ScripsAmerica will gain 100% ownership of the pharmaceutical distribution upon completion of their merger, which is expected to be complete by December 2012.

Potential Acquisition Target

SCRC's growing distribution network of generic drugs to both private and government agencies may eventually make ScripsAmerica an attractive acquisition target for a larger NASDAQ or AMEX company looking to enter, or expand their own generic supplier footprint. The odds of SCRC becoming an attractive target should increase if and when they close the merger with Marlex Pharmaceuticals.

Register here to receive updates and to be added to SCRC investor mailing list online by going to http://www.wallstreetnewscast.com/request/scrc.html 

This investor presentation may include statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

Disclaimer:

This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast ("WSNC") does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. WSNC, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Wall Street Newscast was compensated one thousand seven hundred dollars, and twenty five thousand restricted shares, for ongoing research and media coverage. WSNC may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.